Waters Corporation (WAT), the analytical-instruments maker behind liquid chromatography, mass spectrometry, and thermal-analysis systems, has been one of the most dramatically re-rated names in the life-sciences-tools sector since it closed its combination with Becton Dickinson's Biosciences and Diagnostic Solutions business in February 2026. With shares trading near a record high, investors are asking whether the stock can push toward $515.
The $515 figure used here is not an aggregate consensus. Because Waters' stock has rallied sharply, the average analyst price target has essentially converged with the market price, leaving no meaningful upside buffer. S&P Global data shows about 23 analysts covering the stock with a mean target near $466 and a wide range from roughly $349 to $530. Since that mean sits only marginally above the current price, it does not provide a usable 10%-plus upside objective.
Instead, the $515 level is the top tier of named, current analyst objectives. TD Cowen raised its target to $515 from $475 in October 2026, and Goldman Sachs lifted its target to $515 from $465 in September. Other recent moves reflect a broadly positive, if contested, view: Barclays went to $500, Guggenheim to $490, UBS upgraded the stock to Buy with a $490 target, Piper Sandler upgraded to Overweight with $480, and Citi set $470. Meanwhile, Bank of America, J.P. Morgan, Morgan Stanley, and Bernstein hold targets of $465, $435, $430, and $450, respectively, reflecting the cautious side of the Street.
Waters closed near $462.72 in late October 2026, just below an intraday record around $482. Reaching $515 implies roughly 11% additional upside, a modest move relative to the stock's roughly 35% gain over the prior 52 weeks. The path depends on whether the combined company can translate the BDS deal into sustained revenue and margin expansion. Consensus adjusted EPS (earnings per share) for fiscal 2026 is near $14.58, and the forward P/E (price-to-earnings ratio) sits in the high-20s to low-30s range, leaving room for multiple expansion only if execution stays on track.
The stock has spent the year climbing from a 52-week low near $282.77 to a record high around $482.28. The 50-day moving average sits near $424 to $430, and the 200-day average is closer to $367, indicating a firmly established uptrend but also a sizable gap above longer-term support. The psychologically important $500 level is the first milestone ahead of $515, with the recent all-time high around $482 serving as near-term resistance-turned-support if the breakout holds.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ. Key upcoming items include the November 3, 2026 earnings report, fiscal-2026 guidance and any 2027 outlook, progress on BDS synergies and deleveraging, and further analyst target revisions. Investors should also watch macroeconomic inputs such as interest-rate policy, pharma capital-expenditure trends, and China demand, all of which can move instrument orders and the stock's multiple.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single indicator, the system distills large volumes of data into actionable, easy-to-scan signals. Traders can use these tools to discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone. If you are looking for a systematic way to track names like Waters alongside the broader market, consider exploring the AI Daily Buy/Sell Signals dashboard.
The question of whether Waters can reach $515 hinges less on a consensus forecast than on execution. The $515 level reflects the top tier of current analyst objectives and a technical milestone above the stock's record high, requiring roughly 11% upside from recent prices. Support comes from the completed BDS combination, a restructured portfolio, and upward analyst revisions. The principal obstacles are integration costs, elevated leverage, negative GAAP earnings and free cash flow, and stiff competition. With the average analyst target near $466 sitting essentially flat to the price, and individual targets spanning roughly $349 to $530, Wall Street is genuinely divided. The next earnings report and any synergy or deleveraging milestones will be the most important signposts for whether that next leg toward $515 is realistic.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | +3.63% | ||
| A - WAT | 67% Closely correlated | +2.97% | ||
| RVTY - WAT | 60% Loosely correlated | +3.14% | ||
| TMO - WAT | 60% Loosely correlated | +0.87% | ||
| BRKR - WAT | 58% Loosely correlated | +3.10% | ||
| RGEN - WAT | 56% Loosely correlated | +6.47% | ||
More | ||||